Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
BRCA1 Protein | 20 | 2023 | 199 | 2.180 |
Why?
|
Genetic Predisposition to Disease | 34 | 2023 | 2267 | 2.040 |
Why?
|
BRCA2 Protein | 16 | 2023 | 157 | 1.890 |
Why?
|
Breast Neoplasms | 28 | 2023 | 2881 | 1.840 |
Why?
|
Precision Medicine | 9 | 2021 | 394 | 1.690 |
Why?
|
Ovarian Neoplasms | 15 | 2023 | 738 | 1.610 |
Why?
|
Pharmacogenetics | 7 | 2024 | 434 | 1.440 |
Why?
|
Genetic Testing | 8 | 2021 | 535 | 1.250 |
Why?
|
Mutation | 24 | 2023 | 3952 | 1.140 |
Why?
|
Genes, BRCA2 | 7 | 2019 | 160 | 1.060 |
Why?
|
Genes, BRCA1 | 7 | 2019 | 192 | 1.050 |
Why?
|
Primary Health Care | 3 | 2021 | 339 | 0.920 |
Why?
|
Germ-Line Mutation | 8 | 2023 | 329 | 0.880 |
Why?
|
Heterozygote | 16 | 2023 | 365 | 0.870 |
Why?
|
Genetics, Population | 2 | 2021 | 394 | 0.790 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2021 | 57 | 0.770 |
Why?
|
Genome-Wide Association Study | 12 | 2021 | 1611 | 0.760 |
Why?
|
Polymorphism, Single Nucleotide | 17 | 2022 | 2350 | 0.740 |
Why?
|
Patients | 1 | 2021 | 100 | 0.730 |
Why?
|
Health Literacy | 1 | 2021 | 70 | 0.710 |
Why?
|
Prostatic Neoplasms | 9 | 2022 | 1708 | 0.700 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 199 | 0.630 |
Why?
|
Genomics | 5 | 2021 | 710 | 0.520 |
Why?
|
Humans | 70 | 2024 | 86281 | 0.510 |
Why?
|
Chromosomes, Human, Pair 9 | 2 | 2016 | 86 | 0.500 |
Why?
|
Early Detection of Cancer | 2 | 2014 | 387 | 0.480 |
Why?
|
Risk Factors | 21 | 2024 | 5397 | 0.460 |
Why?
|
Female | 47 | 2023 | 44405 | 0.440 |
Why?
|
Delivery of Health Care | 2 | 2018 | 423 | 0.440 |
Why?
|
Pharmacogenomic Testing | 3 | 2018 | 97 | 0.430 |
Why?
|
Patient Acceptance of Health Care | 1 | 2014 | 237 | 0.420 |
Why?
|
Physicians | 2 | 2021 | 672 | 0.380 |
Why?
|
Adult | 28 | 2024 | 25577 | 0.380 |
Why?
|
Risk Assessment | 9 | 2023 | 2253 | 0.380 |
Why?
|
Middle Aged | 25 | 2021 | 24957 | 0.380 |
Why?
|
Comparative Genomic Hybridization | 1 | 2010 | 39 | 0.370 |
Why?
|
Cytogenetic Analysis | 1 | 2010 | 71 | 0.370 |
Why?
|
Alleles | 6 | 2021 | 1127 | 0.350 |
Why?
|
Mendelian Randomization Analysis | 2 | 2019 | 43 | 0.340 |
Why?
|
Body Height | 2 | 2019 | 99 | 0.340 |
Why?
|
Mastectomy | 3 | 2016 | 234 | 0.340 |
Why?
|
Chromosome Aberrations | 1 | 2010 | 386 | 0.320 |
Why?
|
Abnormalities, Multiple | 1 | 2010 | 232 | 0.320 |
Why?
|
Neoplasms | 5 | 2023 | 2889 | 0.320 |
Why?
|
Pedigree | 7 | 2020 | 966 | 0.310 |
Why?
|
Patient Reported Outcome Measures | 2 | 2021 | 165 | 0.310 |
Why?
|
Quantitative Trait Loci | 6 | 2021 | 576 | 0.290 |
Why?
|
Chromosome Mapping | 3 | 2020 | 1074 | 0.290 |
Why?
|
Male | 25 | 2024 | 40860 | 0.280 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2020 | 455 | 0.270 |
Why?
|
Body Mass Index | 2 | 2019 | 770 | 0.270 |
Why?
|
Aged | 17 | 2024 | 18353 | 0.260 |
Why?
|
Receptors, Estrogen | 3 | 2020 | 382 | 0.260 |
Why?
|
Prostate | 2 | 2022 | 374 | 0.260 |
Why?
|
Biomarkers, Tumor | 3 | 2021 | 1461 | 0.240 |
Why?
|
Patient Transfer | 1 | 2014 | 91 | 0.230 |
Why?
|
Community Health Planning | 3 | 2018 | 21 | 0.230 |
Why?
|
Phenotype | 7 | 2023 | 2375 | 0.230 |
Why?
|
Software | 2 | 2020 | 650 | 0.220 |
Why?
|
DNA Copy Number Variations | 3 | 2022 | 171 | 0.220 |
Why?
|
Aged, 80 and over | 7 | 2021 | 6481 | 0.220 |
Why?
|
Case-Control Studies | 7 | 2020 | 1801 | 0.220 |
Why?
|
Exome | 3 | 2021 | 127 | 0.210 |
Why?
|
Young Adult | 7 | 2021 | 5961 | 0.200 |
Why?
|
Inpatients | 1 | 2014 | 295 | 0.200 |
Why?
|
Health Personnel | 2 | 2021 | 202 | 0.200 |
Why?
|
Heart Arrest | 1 | 2014 | 264 | 0.200 |
Why?
|
Intensive Care Units | 1 | 2014 | 373 | 0.200 |
Why?
|
Electronic Health Records | 1 | 2014 | 319 | 0.200 |
Why?
|
Genetic Variation | 3 | 2019 | 1349 | 0.200 |
Why?
|
Mutation, Missense | 2 | 2020 | 276 | 0.200 |
Why?
|
Genotype | 7 | 2021 | 1850 | 0.200 |
Why?
|
Venous Thromboembolism | 1 | 2023 | 151 | 0.190 |
Why?
|
Urogenital Abnormalities | 1 | 2020 | 19 | 0.190 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2020 | 57 | 0.190 |
Why?
|
Patient Readmission | 1 | 2024 | 324 | 0.190 |
Why?
|
Thrombosis | 1 | 2023 | 296 | 0.190 |
Why?
|
Urinary Tract | 1 | 2020 | 32 | 0.190 |
Why?
|
Lung Neoplasms | 3 | 2023 | 2260 | 0.180 |
Why?
|
Cystic Fibrosis | 1 | 2020 | 112 | 0.180 |
Why?
|
Prospective Studies | 7 | 2023 | 4194 | 0.180 |
Why?
|
Forkhead Transcription Factors | 1 | 2020 | 166 | 0.180 |
Why?
|
Illinois | 1 | 2021 | 461 | 0.180 |
Why?
|
Hereditary Sensory and Motor Neuropathy | 1 | 2019 | 2 | 0.180 |
Why?
|
Nipples | 2 | 2016 | 35 | 0.170 |
Why?
|
Hexokinase | 1 | 2019 | 19 | 0.170 |
Why?
|
Inheritance Patterns | 1 | 2019 | 48 | 0.170 |
Why?
|
Alzheimer Disease | 1 | 2023 | 470 | 0.170 |
Why?
|
Epigenesis, Genetic | 2 | 2020 | 476 | 0.170 |
Why?
|
Databases, Genetic | 3 | 2018 | 259 | 0.170 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2023 | 566 | 0.160 |
Why?
|
Erythrocytes | 1 | 2019 | 255 | 0.160 |
Why?
|
Internationality | 1 | 2018 | 69 | 0.160 |
Why?
|
Prognosis | 6 | 2019 | 3669 | 0.160 |
Why?
|
Surveys and Questionnaires | 3 | 2021 | 2495 | 0.160 |
Why?
|
Retrospective Studies | 9 | 2024 | 8431 | 0.150 |
Why?
|
Exons | 2 | 2016 | 450 | 0.150 |
Why?
|
Transcriptome | 2 | 2020 | 574 | 0.150 |
Why?
|
Genes, Modifier | 1 | 2017 | 5 | 0.150 |
Why?
|
Repressor Proteins | 1 | 2020 | 403 | 0.150 |
Why?
|
Genetic Association Studies | 4 | 2020 | 294 | 0.150 |
Why?
|
Community Pharmacy Services | 1 | 2016 | 5 | 0.150 |
Why?
|
DNA-Binding Proteins | 2 | 2020 | 1208 | 0.150 |
Why?
|
Tumor Suppressor Proteins | 2 | 2016 | 279 | 0.150 |
Why?
|
Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 52 | 0.150 |
Why?
|
Professional Role | 1 | 2016 | 41 | 0.140 |
Why?
|
Homeodomain Proteins | 1 | 2020 | 535 | 0.140 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2016 | 59 | 0.140 |
Why?
|
Genetic Carrier Screening | 1 | 2016 | 60 | 0.140 |
Why?
|
Adenomatous Polyps | 1 | 2016 | 11 | 0.140 |
Why?
|
Point Mutation | 2 | 2016 | 246 | 0.140 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2016 | 65 | 0.140 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2017 | 74 | 0.140 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2021 | 508 | 0.140 |
Why?
|
Adenomatous Polyposis Coli Protein | 1 | 2016 | 39 | 0.140 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2016 | 39 | 0.140 |
Why?
|
Codon, Terminator | 1 | 2015 | 21 | 0.140 |
Why?
|
Breast Neoplasms, Male | 1 | 2016 | 30 | 0.140 |
Why?
|
Medical History Taking | 1 | 2016 | 80 | 0.140 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 1610 | 0.140 |
Why?
|
Genes, Dominant | 1 | 2015 | 117 | 0.140 |
Why?
|
Genetic Loci | 1 | 2017 | 250 | 0.140 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2016 | 125 | 0.140 |
Why?
|
Cohort Studies | 4 | 2024 | 2759 | 0.130 |
Why?
|
Proportional Hazards Models | 3 | 2019 | 857 | 0.130 |
Why?
|
Connective Tissue Diseases | 1 | 2015 | 67 | 0.130 |
Why?
|
Estrogen Receptor alpha | 1 | 2016 | 144 | 0.130 |
Why?
|
Colorectal Neoplasms | 2 | 2020 | 924 | 0.130 |
Why?
|
Linkage Disequilibrium | 3 | 2021 | 473 | 0.130 |
Why?
|
Ovariectomy | 1 | 2014 | 81 | 0.130 |
Why?
|
Patient Care Team | 1 | 2016 | 280 | 0.120 |
Why?
|
Mucin-1 | 1 | 2014 | 44 | 0.120 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2023 | 1372 | 0.120 |
Why?
|
Risk Reduction Behavior | 1 | 2014 | 98 | 0.120 |
Why?
|
Estrone | 1 | 2013 | 10 | 0.120 |
Why?
|
G2 Phase | 1 | 2013 | 34 | 0.120 |
Why?
|
Adolescent | 6 | 2020 | 8968 | 0.120 |
Why?
|
Membrane Glycoproteins | 1 | 2015 | 428 | 0.110 |
Why?
|
Cell Cycle Proteins | 1 | 2016 | 388 | 0.110 |
Why?
|
Infant | 3 | 2020 | 3036 | 0.110 |
Why?
|
Stomach Neoplasms | 1 | 2016 | 266 | 0.110 |
Why?
|
Patient Satisfaction | 1 | 2016 | 452 | 0.110 |
Why?
|
Transcription Factors | 1 | 2020 | 1555 | 0.110 |
Why?
|
Survival Analysis | 3 | 2019 | 1536 | 0.110 |
Why?
|
Polycystic Kidney, Autosomal Dominant | 1 | 2014 | 136 | 0.110 |
Why?
|
Carrier Proteins | 1 | 2016 | 672 | 0.110 |
Why?
|
Cell Division | 1 | 2013 | 696 | 0.100 |
Why?
|
Prostate-Specific Antigen | 1 | 2014 | 346 | 0.100 |
Why?
|
Head and Neck Neoplasms | 1 | 2019 | 1051 | 0.100 |
Why?
|
DNA Mutational Analysis | 4 | 2016 | 526 | 0.100 |
Why?
|
United Kingdom | 2 | 2020 | 164 | 0.090 |
Why?
|
Biological Specimen Banks | 2 | 2020 | 64 | 0.090 |
Why?
|
Micrognathism | 1 | 2010 | 11 | 0.090 |
Why?
|
Eye Abnormalities | 1 | 2010 | 41 | 0.090 |
Why?
|
Karyotyping | 1 | 2010 | 250 | 0.090 |
Why?
|
Bayes Theorem | 2 | 2022 | 360 | 0.090 |
Why?
|
Chromosome Deletion | 1 | 2010 | 228 | 0.090 |
Why?
|
Gene Duplication | 1 | 2010 | 125 | 0.090 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2010 | 348 | 0.090 |
Why?
|
Adenocarcinoma | 1 | 2016 | 1160 | 0.080 |
Why?
|
Chicago | 1 | 2013 | 1377 | 0.080 |
Why?
|
Developmental Disabilities | 1 | 2010 | 194 | 0.080 |
Why?
|
Family | 2 | 2020 | 311 | 0.080 |
Why?
|
Gene Expression | 3 | 2016 | 1281 | 0.080 |
Why?
|
Genome, Human | 1 | 2012 | 756 | 0.080 |
Why?
|
Population Surveillance | 2 | 2019 | 219 | 0.070 |
Why?
|
Multifactorial Inheritance | 1 | 2017 | 158 | 0.070 |
Why?
|
Homozygote | 2 | 2023 | 200 | 0.070 |
Why?
|
Dimensional Measurement Accuracy | 1 | 2014 | 4 | 0.060 |
Why?
|
Risk | 2 | 2016 | 673 | 0.060 |
Why?
|
Protein Binding | 2 | 2020 | 1454 | 0.060 |
Why?
|
Hospital Rapid Response Team | 1 | 2014 | 27 | 0.060 |
Why?
|
Early Diagnosis | 1 | 2014 | 131 | 0.060 |
Why?
|
Odds Ratio | 2 | 2016 | 677 | 0.060 |
Why?
|
RNA, Messenger | 2 | 2022 | 1975 | 0.060 |
Why?
|
Factor V | 1 | 2023 | 10 | 0.060 |
Why?
|
Prothrombin | 1 | 2023 | 18 | 0.060 |
Why?
|
Drug Interactions | 1 | 2024 | 248 | 0.060 |
Why?
|
Social Determinants of Health | 1 | 2024 | 78 | 0.060 |
Why?
|
Apolipoprotein E4 | 1 | 2023 | 27 | 0.060 |
Why?
|
Gene Expression Profiling | 2 | 2019 | 1381 | 0.060 |
Why?
|
Promoter Regions, Genetic | 2 | 2016 | 937 | 0.060 |
Why?
|
Computational Biology | 2 | 2016 | 528 | 0.050 |
Why?
|
Virulence | 1 | 2023 | 270 | 0.050 |
Why?
|
Apolipoproteins E | 1 | 2023 | 129 | 0.050 |
Why?
|
Multicenter Studies as Topic | 1 | 2022 | 156 | 0.050 |
Why?
|
Image-Guided Biopsy | 1 | 2022 | 65 | 0.050 |
Why?
|
Sequence Analysis, DNA | 2 | 2016 | 853 | 0.050 |
Why?
|
Bernard-Soulier Syndrome | 1 | 2000 | 1 | 0.050 |
Why?
|
Gallbladder Neoplasms | 1 | 2020 | 22 | 0.050 |
Why?
|
Amphibian Proteins | 1 | 2020 | 3 | 0.050 |
Why?
|
Biopsy | 2 | 2015 | 1160 | 0.050 |
Why?
|
Calibration | 1 | 2020 | 99 | 0.050 |
Why?
|
Morpholinos | 1 | 2020 | 13 | 0.050 |
Why?
|
Models, Statistical | 1 | 2014 | 574 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2016 | 1196 | 0.050 |
Why?
|
Age Factors | 2 | 2016 | 1842 | 0.050 |
Why?
|
Xenopus | 1 | 2020 | 125 | 0.050 |
Why?
|
Glycine | 1 | 2020 | 90 | 0.050 |
Why?
|
Larva | 1 | 2020 | 117 | 0.050 |
Why?
|
Sequence Deletion | 1 | 2020 | 205 | 0.050 |
Why?
|
Glutamic Acid | 1 | 2020 | 152 | 0.050 |
Why?
|
Neoplasm Staging | 2 | 2016 | 1932 | 0.050 |
Why?
|
Vesicular Transport Proteins | 1 | 2020 | 63 | 0.050 |
Why?
|
Bronchi | 1 | 2020 | 229 | 0.040 |
Why?
|
Cell Line | 2 | 2015 | 2466 | 0.040 |
Why?
|
Amino Acid Substitution | 1 | 2020 | 339 | 0.040 |
Why?
|
Menopause | 1 | 2019 | 71 | 0.040 |
Why?
|
Retinitis Pigmentosa | 1 | 2019 | 35 | 0.040 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 2020 | 148 | 0.040 |
Why?
|
Haploinsufficiency | 1 | 2019 | 62 | 0.040 |
Why?
|
Estrogens | 1 | 2020 | 197 | 0.040 |
Why?
|
Mice | 3 | 2020 | 11313 | 0.040 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2020 | 261 | 0.040 |
Why?
|
Gene Frequency | 1 | 2020 | 676 | 0.040 |
Why?
|
Child | 2 | 2020 | 6913 | 0.040 |
Why?
|
Triple Negative Breast Neoplasms | 1 | 2020 | 136 | 0.040 |
Why?
|
Telomere-Binding Proteins | 1 | 2017 | 14 | 0.040 |
Why?
|
Pregnancy-Specific beta 1-Glycoproteins | 1 | 2017 | 1 | 0.040 |
Why?
|
Transcription Factors, TFII | 1 | 2017 | 2 | 0.040 |
Why?
|
Cytochrome P450 Family 2 | 1 | 2017 | 4 | 0.040 |
Why?
|
Glutamate Carboxypeptidase II | 1 | 2017 | 8 | 0.040 |
Why?
|
Geography | 1 | 2018 | 223 | 0.040 |
Why?
|
Disclosure | 1 | 2018 | 108 | 0.040 |
Why?
|
Meta-Analysis as Topic | 1 | 2017 | 87 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 2 | 2022 | 3347 | 0.040 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2017 | 44 | 0.040 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2016 | 106 | 0.040 |
Why?
|
Carcinogenesis | 1 | 2018 | 194 | 0.040 |
Why?
|
Allelic Imbalance | 1 | 2016 | 20 | 0.040 |
Why?
|
Incidence | 1 | 2020 | 1568 | 0.040 |
Why?
|
Loss of Heterozygosity | 1 | 2016 | 85 | 0.040 |
Why?
|
Thyroid Neoplasms | 1 | 2020 | 406 | 0.030 |
Why?
|
Public Health | 1 | 2017 | 129 | 0.030 |
Why?
|
RNA Splice Sites | 1 | 2016 | 53 | 0.030 |
Why?
|
Physicians, Primary Care | 1 | 2017 | 104 | 0.030 |
Why?
|
Gastric Mucosa | 1 | 2016 | 66 | 0.030 |
Why?
|
Mice, Knockout | 1 | 2020 | 1918 | 0.030 |
Why?
|
Neoplasm Grading | 1 | 2016 | 356 | 0.030 |
Why?
|
Neoplasm Proteins | 1 | 2019 | 532 | 0.030 |
Why?
|
Mental Disorders | 1 | 2019 | 371 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2019 | 7949 | 0.030 |
Why?
|
Lysine | 1 | 2015 | 147 | 0.030 |
Why?
|
Sequence Alignment | 1 | 2015 | 351 | 0.030 |
Why?
|
RNA Splicing | 1 | 2016 | 142 | 0.030 |
Why?
|
Nucleotides | 1 | 2015 | 95 | 0.030 |
Why?
|
Smoking | 1 | 2019 | 605 | 0.030 |
Why?
|
Self Report | 1 | 2016 | 287 | 0.030 |
Why?
|
Alternative Splicing | 1 | 2016 | 201 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2015 | 369 | 0.030 |
Why?
|
Age of Onset | 1 | 2015 | 306 | 0.030 |
Why?
|
Genetic Linkage | 1 | 2016 | 623 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2020 | 2699 | 0.030 |
Why?
|
Enhancer Elements, Genetic | 1 | 2016 | 266 | 0.030 |
Why?
|
United States | 2 | 2024 | 6637 | 0.030 |
Why?
|
Haplotypes | 1 | 2016 | 642 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2015 | 551 | 0.030 |
Why?
|
Child, Preschool | 1 | 2020 | 3608 | 0.030 |
Why?
|
Animals | 3 | 2020 | 26518 | 0.030 |
Why?
|
Gene-Environment Interaction | 1 | 2014 | 103 | 0.030 |
Why?
|
Skin | 1 | 2015 | 554 | 0.030 |
Why?
|
Attitude of Health Personnel | 1 | 2017 | 636 | 0.030 |
Why?
|
Base Sequence | 1 | 2016 | 2329 | 0.030 |
Why?
|
Logistic Models | 1 | 2015 | 1184 | 0.030 |
Why?
|
Amino Acid Sequence | 1 | 2015 | 2062 | 0.030 |
Why?
|
Data Collection | 1 | 2012 | 371 | 0.020 |
Why?
|
Molecular Sequence Data | 1 | 2015 | 3029 | 0.020 |
Why?
|
Phosphorylation | 1 | 2013 | 1101 | 0.020 |
Why?
|
Survival Rate | 1 | 2014 | 1856 | 0.020 |
Why?
|
Fibroblasts | 1 | 2013 | 729 | 0.020 |
Why?
|
Registries | 1 | 2014 | 702 | 0.020 |
Why?
|
Patient Selection | 1 | 2014 | 685 | 0.020 |
Why?
|
Disease Progression | 1 | 2014 | 1531 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2014 | 1671 | 0.020 |
Why?
|
Carcinoma, Renal Cell | 1 | 2013 | 425 | 0.020 |
Why?
|
Kidney Failure, Chronic | 1 | 2014 | 509 | 0.020 |
Why?
|
Quality of Life | 1 | 2016 | 1575 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2014 | 1305 | 0.020 |
Why?
|
Kidney | 1 | 2014 | 1240 | 0.020 |
Why?
|
Kidney Neoplasms | 1 | 2013 | 620 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2014 | 3616 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2013 | 2421 | 0.020 |
Why?
|
Time Factors | 1 | 2014 | 5198 | 0.020 |
Why?
|
Platelet Glycoprotein GPIb-IX Complex | 1 | 2000 | 6 | 0.010 |
Why?
|
Consensus Sequence | 1 | 2000 | 64 | 0.010 |
Why?
|
Africa | 1 | 2000 | 98 | 0.010 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2000 | 110 | 0.010 |
Why?
|
Microsatellite Repeats | 1 | 2000 | 141 | 0.010 |
Why?
|
Family Health | 1 | 2000 | 162 | 0.010 |
Why?
|
Polymorphism, Genetic | 1 | 2000 | 819 | 0.010 |
Why?
|